Navigation Links
SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
Date:2/2/2010

AMSTERDAM, February 2 /PRNewswire/ -- SynCo Bio Partners B.V. today announced that it has signed two commercial manufacturing agreements with an undisclosed US biopharmaceutical company. Under the contract, SynCo will provide both process validation and GMP commercial manufacturing services to support the commercial launch of two separate biopharmaceutical products onto the US market.

SynCo has commenced with preparations for the manufacture of conformance lots in advance of its client's BLA filings, expected in late 2010, in anticipation of commercial manufacturing commencing in 2011.

The products are both recombinant proteins, to be produced in E. coli. These products will be manufactured in SynCo's large-scale GMP facility and take the tally of marketed products manufactured at its Amsterdam facilities to six, since SynCo's inception in 2000. SynCo has previously supported process development efforts for both products; an excellent example of how SynCo supports its clients' biopharmaceutical development programs from early stage to commercial supply.

Pierre Warffemius, CEO of SynCo Bio Partners said, "This news is a further example of how SynCo can offer a viable long-term manufacturing choice to its clients. SynCo has grown steadily over the last ten years in a very competitive market. The foundation of this growth has been our ability to form strong and mutually beneficial relationships with our clients. As a consequence, SynCo is one of few biopharmaceutical CMOs in the world with a recognized track record in both clinical and commercial manufacturing, providing financial stability that allows us to continuously invest in our facilities."

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substan
'/>"/>

SOURCE SynCo Bio Partners B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
2. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
3. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
4. SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
5. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... Albany, NY (PRWEB) July 26, 2014 ... 2020 provides key market data on the Canada ... in millions of US dollars, volume (in units) ... segments - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy ... Browse Full Report at http://www.marketresearchreports.biz/analysis/213254 . , ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... THOUSAND OAKS, Calif. , July 25, 2014 /PRNewswire/ ... its Board of Directors today declared a $0.61 per ... dividend will be paid on Sept. 5, 2014, to ... business on Aug. 14, 2014.  About ... biology for patients suffering from serious illnesses by discovering, ...
(Date:7/25/2014)... live in each person,s digestive tract. Scientists believe that ... off harmful infections, but their role in human health ... on the role of these bacteria, a team of ... tracked fluctuations in the bacterial populations of two research ... the July 25 issue of the journal Genome ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... December 2 NicOx S.A.,(NYSE Euronext Paris: ... agreement with,DSM for the commercial manufacture and ... pharmaceutical ingredient). Naproxcinod is NicOx, lead,investigational product ... Oxide-Donating (CINOD) class of,anti-inflammatory agents, which recently ...
... (Pink Sheets: CGCP), a leading developer of surgical products used ... announced the addition of veteran medical device executive and an ... of the Company,s Board of Directors, increasing the number of ... Mr. Cohen, 49, has over 25 years of executive ...
... SHANGHAI, China, Dec. 2 /PRNewswire-Asia/ -- WuXi PharmaTech ... pharmaceutical, biotechnology and medical device,research and development outsourcing ... today announced it will dedicate its Philadelphia facility ... cell therapy,services, and as of December 31, 2008, ...
Cached Biology Technology:NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 2Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 3WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 2WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 3WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 4WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services 5
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... strike that wiped them out if it had taken ... , A fresh study using up-to-date fossil records and ... new narrative of the prehistoric creatures, demise, some 66 ... few million years before a 10km-wide asteroid struck what ... included extensive volcanic activity, changing sea levels and varying ...
(Date:7/27/2014)... the largest prevalence studies to date, researchers from the ... for the hepatitis C virus (HCV). Findings published in ... Study of Liver Diseases, indicate that genotype 1 is ... infected of which one-third reside in East Asia. Genotype ... next most prevalent, followed by genotypes 2, 4, 6, ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2Hepatitis C virus genotype 1 is most prevalent worldwide 2
... How,s this for precision? Researchers with the University of ... knock single atoms off a silicon wafer without disturbing ... engineering professor Vince Donnelly and Demetre Economou, Hugh Roy ... same department, are supported in this project by an ...
... to share knowledge, projects and developments in ... creation of synergies and possible frameworks for ... and institutions that address this matter. ... and will be open untill November 11th., ...
... at the National Science Foundation (NSF)--working cooperatively with ... field science supported by the U.S. Antarctic Program, ... to the maximum extent possible, following the October ... a Presidential mandate to manage the U.S. Antarctic ...
Cached Biology News:Creating smaller, and more powerful, integrated circuits 2NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible 2NSF, US Antarctic Program partners, working to restore Antarctic research season to the maximum extent possible 3
... 384, compatible with hood ... handling system for 384-well ... accurately prepares large quantities ... The Wellpro also performs ...
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
... has been determined, the challenge is to ... audience of scientists, educators and students. Current ... over the Internet, either via online journals ... literature has the advantage of wide acceptance ...
... 45° Fixed Angle rotor for ... CL2, Centra CL3/CL3R, HN-SII or ... style rotor accepts 15 mL ... disposable conical tubes as well ...
Biology Products: